Arbutus Biopharma Corporation
US ˙ NasdaqGS ˙ CA03879J1003

Introduction

This page provides a comprehensive analysis of the known insider trading history of Sofia Michael J.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Sofia Michael J. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ABUS / Arbutus Biopharma Corporation Chief Scientific Officer 1,485,121
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Sofia Michael J.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ABUS / Arbutus Biopharma Corporation - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ABUS / Arbutus Biopharma Corporation. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ABUS / Arbutus Biopharma Corporation Insider Trades
Insider Sales ABUS / Arbutus Biopharma Corporation - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ABUS / Arbutus Biopharma Corporation. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2018-08-13 ABUS Sofia Michael J. 4,250 9.5143 4,250 9.5143 40,436 305 1.46 -34,230 -84.65
2017-08-15 ABUS Sofia Michael J. 10,000 3.7500 10,000 3.7500 37,500
2017-08-15 ABUS Sofia Michael J. 20,000 3.6750 20,000 3.6750 73,500

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ABUS / Arbutus Biopharma Corporation Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Sofia Michael J. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-02-05 2024-02-02 4 ABUS Arbutus Biopharma Corp
Common Shares
S - Sale X -9,982 1,485,121 -0.67 2.31 -23,083 3,434,342
2024-02-05 2024-02-01 4 ABUS Arbutus Biopharma Corp
Common Shares
A - Award 109,500 1,495,103 7.90
2023-02-03 2023-02-01 4 ABUS Arbutus Biopharma Corp
Common Shares
A - Award 82,200 1,385,603 6.31
2022-01-20 2022-01-20 4 ABUS Arbutus Biopharma Corp
Stock Option (Right to Buy)
A - Award 285,000 285,000 2.81 800,850 800,850
2021-12-03 2021-12-01 4 ABUS Arbutus Biopharma Corp
Common Shares
S - Sale X -200,000 1,303,403 -13.30 5.09 -1,018,000 6,634,321
2021-02-17 2021-02-13 4 ABUS Arbutus Biopharma Corp
Stock Options
A - Award 290,000 290,000
2020-02-19 2020-02-17 4 ABUS Arbutus Biopharma Corp
Stock Options
A - Award 250,000 250,000
2019-03-05 2019-03-01 4 ABUS Arbutus Biopharma Corp
Employee Stock Option (Right to Buy)
A - Award 145,000 145,000
2018-08-15 2018-08-13 4/A ABUS Arbutus Biopharma Corp
Common Shares
S - Sale -4,250 167,162 -2.48 9.51 -40,436 1,590,429
2018-08-14 2018-08-13 4 ABUS Arbutus Biopharma Corp
Common Shares
S - Sale -4,250 1,499,153 -0.28 9.51 -40,436 14,263,391
2018-07-13 2018-07-11 4 ABUS Arbutus Biopharma Corp
Common Shares
S - Sale X -10,000 1,503,403 -0.66 10.00 -100,000 15,034,030
2018-07-10 2018-07-09 4 ABUS Arbutus Biopharma Corp
Common Shares
S - Sale X -10,000 1,513,403 -0.66 8.91 -89,060 13,478,367
2018-07-10 2018-07-06 4 ABUS Arbutus Biopharma Corp
Common Shares
S - Sale X -10,000 1,523,403 -0.65 8.45 -84,500 12,872,755
2018-07-06 2018-07-05 4 ABUS Arbutus Biopharma Corp
Common Shares
S - Sale X -10,000 1,533,403 -0.65 8.40 -84,000 12,880,585
2018-07-06 2018-07-03 4 ABUS Arbutus Biopharma Corp
Common Shares
S - Sale X -10,000 1,543,403 -0.64 8.00 -80,000 12,347,224
2018-04-18 2018-04-16 4 ABUS Arbutus Biopharma Corp
Employee Stock Option (Right to Buy)
A - Award 160,000 160,000
2017-10-05 2017-10-03 4 ABUS Arbutus Biopharma Corp
Common Shares
S - Sale X -10,000 1,553,403 -0.64 8.00 -80,000 12,427,224
2017-08-17 2017-08-15 4 ABUS Arbutus Biopharma Corp
Common Shares
S - Sale -20,000 171,412 -10.45 3.68 -73,500 629,939
2017-08-17 2017-08-15 4 ABUS Arbutus Biopharma Corp
Common Shares
S - Sale -10,000 191,412 -4.96 3.75 -37,500 717,795
2017-04-05 2017-03-24 4 ABUS Arbutus Biopharma Corp
Employee Stock Option (Right to Buy)
A - Award 150,000 150,000
2016-03-17 2016-03-15 4 ABUS Arbutus Biopharma Corp
Employee Stock Option (Right to Buy)
A - Award 100,000 100,000
2015-03-16 3 TKMR TEKMIRA PHARMACEUTICALS Corp
Common Stock
3,328,218
2015-03-16 3 TKMR TEKMIRA PHARMACEUTICALS Corp
Common Stock
1,966,227
2015-03-16 3 TKMR TEKMIRA PHARMACEUTICALS Corp
Common Stock
3,328,218
2015-03-16 3 TKMR TEKMIRA PHARMACEUTICALS Corp
Common Stock
1,966,227
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)